ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 21.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,951 shares of the specialty pharmaceutical company’s stock after selling 9,020 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ANI Pharmaceuticals were worth $2,026,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in ANI Pharmaceuticals during the second quarter worth about $65,000. Ridgewood Investments LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $85,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after buying an additional 579 shares during the period. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $207,000. Finally, Profund Advisors LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $225,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,731 shares of company stock valued at $2,015,861 in the last three months. Corporate insiders own 12.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ANIP shares. Raymond James upped their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $56.59 on Monday. ANI Pharmaceuticals, Inc. has a 1 year low of $51.79 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a 50 day moving average price of $58.01 and a 200 day moving average price of $60.29. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -102.89 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the business earned $1.05 EPS. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.